Literature DB >> 22837189

Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance.

Helen Jones1, Victoria S Sprung, Christopher J A Pugh, Christina Daousi, Andrew Irwin, Nabil Aziz, Valerie L Adams, E Louise Thomas, Jimmy D Bell, Graham J Kemp, Daniel J Cuthbertson.   

Abstract

CONTEXT: Nonalcoholic fatty liver disease may be evident in women with polycystic ovary syndrome (PCOS), both conditions being associated with obesity and insulin resistance. However, few studies have accounted for the high prevalence of obesity in PCOS.
OBJECTIVE: The aim of this study was to determine whether PCOS is independently associated with hepatic steatosis, compared with healthy controls of similar age and body mass index (BMI), and whether steatosis is associated with hyperandrogenemia. DESIGN AND
SETTING: We conducted a cross-sectional, case-control study at two tertiary referral centers. PATIENTS: Twenty-nine women with PCOS diagnosed by the Rotterdam criteria [aged 28 yr; 95% confidence interval (CI), 26-31; BMI, 33 kg/m2; 95% CI, 31-36] and 22 healthy controls (aged 29 yr; 95% CI, 28-31; BMI, 30 kg/m2; 95% CI, 28-33) were studied.
METHODS: Proton-magnetic resonance spectroscopy quantified hepatic and skeletal muscle fat; whole body magnetic resonance imaging quantified internal, visceral, and sc adipose tissue volumes. Differences were assessed between PCOS and controls using t tests, and between hyperandrogenic (HA) PCOS, PCOS with normal androgens (NA), and controls using analysis of covariance.
RESULTS: After statistical adjustment for BMI, HA-PCOS had significantly higher liver fat vs. NA-PCOS (3.7%; 95% CI, 0.6-13.1) and vs. controls (2.1%; 95% CI, 0.3-6.6). Similarly, after adjustment for homeostasis model assessment for insulin resistance, internal and visceral adipose tissue volumes, liver fat remained significantly greater in HA-PCOS compared to NA-PCOS and controls.
CONCLUSION: These data suggest that HA-PCOS is associated with hepatic steatosis, independent of obesity and insulin resistance.

Entities:  

Mesh:

Year:  2012        PMID: 22837189     DOI: 10.1210/jc.2012-1382

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  74 in total

Review 1.  Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.

Authors:  A L L Rocha; L C Faria; T C M Guimarães; G V Moreira; A L Cândido; C A Couto; F M Reis
Journal:  J Endocrinol Invest       Date:  2017-06-13       Impact factor: 4.256

2.  Racial/ethnic differences in hepatic steatosis in a population-based cohort of post-menopausal women: the Michigan Study of Women's Health Across the Nation.

Authors:  C Kim; S D Harlow; C A Karvonen-Gutierrez; J F Randolph; M Helmuth; S Kong; B Nan; R Carlos
Journal:  Diabet Med       Date:  2013-06-07       Impact factor: 4.359

Review 3.  Nonalcoholic fatty liver disease and polycystic ovary syndrome.

Authors:  Evangeline Vassilatou
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 4.  Reproductive Health and Nonalcoholic Fatty Liver Disease in Women: Considerations Across the Reproductive Lifespan.

Authors:  Monika Sarkar; Ayako Suzuki
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-06-30

5.  The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome.

Authors:  Monika Sarkar; Norah Terrault; Caroline C Duwaerts; Phyllis Tien; Marcelle I Cedars; Heather Huddleston
Journal:  Curr Opin Gynecol Obstet       Date:  2018-04-05

Review 6.  Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Authors:  Stavroula A Paschou; Stergios A Polyzos; Panagiotis Anagnostis; Dimitrios G Goulis; Christina Kanaka-Gantenbein; Irene Lambrinoudaki; Neoklis A Georgopoulos; Andromachi Vryonidou
Journal:  Endocrine       Date:  2019-09-19       Impact factor: 3.633

7.  Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Mediators of Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep.

Authors:  Muraly Puttabyatappa; Victoria Andriessen; Makeda Mesquitta; Lixia Zeng; Subramaniam Pennathur; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2017-09-01       Impact factor: 4.736

8.  Low-Dose Dihydrotestosterone Drives Metabolic Dysfunction via Cytosolic and Nuclear Hepatic Androgen Receptor Mechanisms.

Authors:  Stanley Andrisse; Shameka Childress; Yaping Ma; Katelyn Billings; Yi Chen; Ping Xue; Ashley Stewart; Momodou L Sonko; Andrew Wolfe; Sheng Wu
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

9.  Lack of Association of Vitamin D Receptor FokI (rs10735810) (C/T) and BsmI (rs1544410) (A/G) Genetic Variations with Polycystic Ovary Syndrome Risk: a Case-control Study from Iranian Azeri Turkish Women.

Authors:  Morteza Bagheri; Isa Abdi Rad; Nima Hosseini Jazani; Fariba Nanbakhsh
Journal:  Maedica (Buchar)       Date:  2012-12

10.  Nitric oxide-mediated cutaneous microvascular function is impaired in polycystic ovary sydrome but can be improved by exercise training.

Authors:  V S Sprung; D J Cuthbertson; C J A Pugh; C Daousi; G Atkinson; N F Aziz; G J Kemp; D J Green; N T Cable; H Jones
Journal:  J Physiol       Date:  2013-01-14       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.